Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Dermatologic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Hematologic Neoplasms 1Burkitt Lymphoma 1

Interventions

venetoclax 308Cyclophosphamide 231Cytarabine 201Azacitidine 191fludarabine 181Specimen Handling 136Biopsy 103fludarabine phosphate 97Methotrexate 82Rituximab 79Daunorubicin 77Dexamethasone 76Vincristine 69Whole-Body Irradiation 64Mycophenolic Acid 59Decitabine 58Tacrolimus 55Etoposide 53ibrutinib 52blinatumomab 51Granulocyte Colony-Stimulating Factor 51obinutuzumab 50Busulfan 50Prednisone 48Melphalan 48acalabrutinib 47Injections 47Stem Cell Transplantation 45Idarubicin 45Magnetic Resonance Spectroscopy 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Methylprednisolone Hemisuccinate × Other hematologic neoplasm × 1 year × Clear all
NCT04438382 2026-06-02

Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis

Eastern Cooperative Oncology Group

Phase 2 Terminated
1 enrolled 1 chart
Other hematologic neoplasm

Hematologic Neoplasms

NCT03913559 2026-02-12

Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia

St. Jude Children's Research Hospital

Phase 2 Terminated
5 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡